• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by Palatin Technologies Inc.

    5/28/26 4:05:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email
    25 1 form25.htm 25

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    FORM 25

     

    NOTIFICATION OF REMOVAL FROM LISTING AND/OR

    REGISTRATION UNDER SECTION 12(b) OF

    THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-15543

     

    Palatin Technologies, Inc.

    NYSE American LLC

     

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

     

    301 Carnegie Center Drive, Suite 304

    Princeton, New Jersey 08540

    (609) 495-2200

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

    Common Stock, par value $0.01 per share

    (Description of class of securities)

     

     

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

    ☐ 17 CFR 240.12d2-2(a)(1)
    ☐ 17 CFR 240.12d2-2(a)(2)
    ☐ 17 CFR 240.12d2-2(a)(3)
    ☐ 17 CFR 240.12d2-2(a)(4)
    ☐ Pursuant to 17 CFR 240.12d2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
    ☒ Pursuant to 17 CFR 240.12d202(c), the Issuer has complied with the rules of the Exchange and requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Palatin Technologies, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    May 28, 2026   By: /s/Stephen T. Wills  

    Executive Vice President, Chief Financial

    Officer and Chief Operating Officer

    Date   Name   Title

     

    1Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

     

     

     

    Get the next $PTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    12/12/2025$60.00Buy
    Laidlaw
    12/3/2025$50.00Buy
    Alliance Global Partners
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    SEC Filings

    View All

    SEC Form CERT filed by Palatin Technologies Inc.

    CERT - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/28/26 5:13:42 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-A12B filed by Palatin Technologies Inc.

    8-A12B - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/28/26 4:07:04 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25 filed by Palatin Technologies Inc.

    25 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/28/26 4:05:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palatin to Begin Trading on Nasdaq Stock Exchange

    PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to

    5/18/26 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndromeOnce-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve t

    5/13/26 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

    Advancing differentiated MC4R-based obesity programs into clinical developmentMelanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndromeOral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving

    2/17/26 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    4/11/24 4:45:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Palatin Technologies with a new price target

    Alliance Global Partners initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $50.00

    12/3/25 7:47:15 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

    11/24/21 6:07:03 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Spana Carl covered exercise/tax liability with 321 shares, decreasing direct ownership by 0.50% to 64,377 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:20 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 212 shares, decreasing direct ownership by 0.33% to 63,276 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:25 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T sold $9,461 worth of shares (565 units at $16.74), decreasing direct ownership by 0.88% to 63,488 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    12/29/25 4:30:13 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Leadership Updates

    Live Leadership Updates

    View All

    Palatin to Begin Trading on Nasdaq Stock Exchange

    PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to

    5/18/26 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Financials

    Live finance-specific insights

    View All

    $PTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndromeOnce-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve t

    5/13/26 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    2/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    2/10/25 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Palatin Technologies Inc. (Amendment)

    SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/24 2:55:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palatin Technologies Inc.

    SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/23 1:19:39 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care